EUVIMEDDescoperă EUVIMED
Crossref

Nirsevimab and Acute Bronchiolitis Admissions in Infants Under One Year of Age

David Andina Martínez iD, Gemma Claret Teruel, Manuel Gijón Mediavilla, Esther Fernández Mozo, Amaia Cámara Otegui, Laura Baños López, Beatriz Jiménez de la Jara, Clara Ferrero García-Loygorri, Victoria Sánchez Tatay, Svetlana Pavlovic Nesic, Nerea González Arza, Verónica Gimeno-Hernández Garza and 6 more

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71249 ↗

At a glance

Journal article in Pediatric Pulmonology, 2025. Written by David Andina Martínez and 17 co-authors. Institution: Pediatric Emergency Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. Major MEDLINE topics: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Bronchiolitis, Viral, Hospitalization. Cited 4 times so far (Crossref); 28 references. Funded by: The authors received no specific funding for this work..

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background and Objectives Spain was among the first countries to implement universal prophylaxis for respiratory syncytial virus (RSV) using nirsevimab, leading to a 60%–80% reduction in bronchiolitis hospital admissions. The main objective of this study was to describe the characteristics of infants admitted with bronchiolitis after RSV prophylaxis had been established.

Methods

A retrospective study was conducted in 15 Spanish pediatric emergency departments during the 2023–2024 RSV season. We reviewed medical records coded as “acute bronchiolitis” of infants aged less than 12 months who were hospitalized.

Results

A total of 947 infants with bronchiolitis were included. Of these, 198 (20.9%) were ineligible for immunization because they were older than 6 months and had no comorbidities. Among the 749 (79.1%) infants who met the criteria for immunization, 377 (50.3%) received nirsevimab, of whom 159 (42.1%) tested positive for RSV, while 372 (49.7%) were not immunized, with 322 (86.5%) testing positive for RSV ( p < 0.001). Among infants who were not immunized, the most common reason for not receiving nirsevimab was family refusal. Among infants with RSV bronchiolitis, there were no significant differences in PICU admission rates or length of stay between those who were immunized and those who were not.

Conclusion

During the first nirsevimab campaign, most bronchiolitis admissions involved healthy children over 6 months of age who were not included in the target population, eligible infants who were not immunized, and immunized infants with non‐RSV bronchiolitis. Further studies are needed to analyze the characteristics of immunized patients who are admitted with RSV bronchiolitis.

Subjects

MeSH terms (MEDLINE)

Respiratory Syncytial Virus InfectionsAntibodies, Monoclonal, HumanizedBronchiolitis, ViralHospitalizationRespiratory Syncytial Virus, HumanHumansMaleInfant, NewbornInfantImmunization ProgramsSpainIntensive Care Units, PediatricRetrospective StudiesAcute DiseaseFemale

Substances

nirsevimabAntibodies, Monoclonal, Humanized

Authors and institutions

  • Pediatric Emergency Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
  • Instituto de Investigación Sanitaria, Hospital Universitario La Princesa, Madrid, Spain.
  • Pediatric Emergency Department, Hospital Sant Joan de Déu, Barcelona, Spain.
  • University of Barcelona, Barcelona, Spain.
  • Environment Effects on Child/Adolescent Well-being, Institut de Recerca Sant Joan de Déu (IRSJD), Barcelona, Spain.
  • Pediatric Emergency Department, Hospital Universitario Doce de Octubre, Madrid, Spain.

ORCID profiles: David Andina Martínez, Jose Antonio Alonso-Cadenas

Funding

  • The authors received no specific funding for this work.

Cite

APA

Andina Martínez, D., Claret Teruel, G., Gijón Mediavilla, M., Fernández Mozo, E., Cámara Otegui, A., Baños López, L., Jiménez de la Jara, B., Ferrero García-Loygorri, C., Sánchez Tatay, V., Pavlovic Nesic, S., González Arza, N., Gimeno-Hernández Garza, V., Guerra Diez, J. L., Ranera Málaga, A., Escalada Pellitero, S., Barrueco Ramos, C., Alonso-Cadenas, J. A., & Impact of Universal Respiratory Syncytial Virus Prophylaxis in Spain Working Group (2025). Nirsevimab and Acute Bronchiolitis Admissions in Infants Under One Year of Age. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71249

Vancouver

Andina Martínez D, Claret Teruel G, Gijón Mediavilla M, Fernández Mozo E, Cámara Otegui A, Baños López L, et al. Nirsevimab and Acute Bronchiolitis Admissions in Infants Under One Year of Age. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71249

BibTeX
@article{AndinaMartnez2025,
  author = {Andina Martínez, David and Claret Teruel, Gemma and Gijón Mediavilla, Manuel and Fernández Mozo, Esther and Cámara Otegui, Amaia and Baños López, Laura and Jiménez de la Jara, Beatriz and Ferrero García-Loygorri, Clara and Sánchez Tatay, Victoria and Pavlovic Nesic, Svetlana and González Arza, Nerea and Gimeno-Hernández Garza, Verónica and Guerra Diez, Jose Lorenzo and Ranera Málaga, Adrián and Escalada Pellitero, Silvia and Barrueco Ramos, Clara and Alonso-Cadenas, Jose Antonio and Impact of Universal Respiratory Syncytial Virus Prophylaxis in Spain Working Group, Impact of Universal Respiratory Syncytial Virus Prophylaxis in Spain Working Group},
  title = {Nirsevimab and Acute Bronchiolitis Admissions in Infants Under One Year of Age},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71249}
}
Start for free →